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orally. in treatment-naïve patients and patients with type 1 Gaucher Disease (GD1) switched from previous en-
zyme replacement therapy (ERT). Clinical evolution, changes in organ size, blood counts, disease biomarkers,
bone marrow infiltration (S-MRI), bone mineral density by broadband ultrasound densitometry (BMD),
safety and tolerability annual reports were analysed. Between May 2004 and April 2016, 63 patients received
miglustat therapy; 20 (32%) untreated and 43 (68%) switched. At the time of this report 39 patients (14 [36%]
treatment-naïve; 25 [64%] switch) remain on miglustat. With over 12-year follow-up, hematologic counts,
liver and spleen volumes remained stable. In total, 80% of patients achieved current GD1 therapeutic goals. Plas-
ma chitotriosidase activity and CCL-18/PARC concentration showed a trend towards a slight increase. Reductions
on S-MRI (p= 0.042)with an increase in BMD (p b 0.01)were registered. Gastrointestinal disturbances were re-
ported in 25/63 (40%), causing miglustat suspension in 11/63 (17.5%) cases. Thirty-eight patients (60%) experi-
enced a fine hand tremor and two a reversible peripheral neuropathy. Overall, miglustat was effective as a long-Keywords:
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Type 1 Gaucher disease (GD1) (OMIM 230800) is an autosomal-re-
cessive inborn disorder of lysosomal metabolism characterized by the
accumulation of glucocerebroside in different organs and systems as a
consequence of the deficient activity of the enzyme, glucocerebrosidase
(acid β-glucosidase). GD1 is a multisystemic disease associated with a
considerable degree of heterogeneity in termsof symptoms type and se-
verity. It is also one of the most common lysosomal storage disorders,
and the first for whichmultiple approved therapies were available [1,2].
Enzyme replacement therapy (ERT) has been used widely to treat
GD1 since 1990 and, in general, studies have demonstrated good effica-
cy and favourable safety/tolerability [3,4,5]. The achievement andmain-
tenance of GD1 therapeutic goals is considered a useful way to monitor
clinical efficacy, and good rates of goal achievement have been reported
in a number of clinical studies assessing ERT [6,7]. However, some GD1
patients on long-term ERT can develop a plateau in their response to
ERT in terms of haematological and visceral disease parameters. The ob-
jective of continued treatment in such patients is to maintain symptom
control and ensure adequate quality of life using themost cost-effective
long-term treatment [6,7,8,9,10].
Miglustat (Zavesca®; Actelion Pharmaceuticals) is an orally
active iminosugar that reversibly inhibits UDP-glucosylceramide
synthase – the enzyme that catalyses the rate-limiting stage in the
glycosphingolipid biosynthesis pathway [11]. Miglustat was approved
in Europe in March 2003 and in the USA in 2004 for use as a substrate
reduction therapy (SRT) in adult patients with mild-to-moderate
GD1 for whom ERT is either unsuitable or is not a therapeutic option
[12,13,14].
There are a number of published data sets on clinical experience
with miglustat in GD1, the majority of which report findings from clin-
ical trials, multicentre retrospective cohorts and case series [15,16,17,
18,19]. In Spain the prospective, observational ZAGAL studywas initiat-
ed by the Spanish Gaucher Disease Foundation after miglustat was
approved by the European Medicines Agency in 2004. We have previ-
ously reported ZAGAL study data regarding the effects of both short-
term (6-month) and long-term (5-year) miglustat therapy during ev-
eryday clinical use in treatment-naïve patients and those previously
treated with ERT [15,16]. Here, we report the long-term efficacy, safety
and tolerability ofmiglustat in ZAGAL study patientswithmild-to-mod-
erate GD1 treated in clinical practice settings during a follow-up period
of 12 years.2. Methods
2.1. Study design
The ZAGAL study is a prospective observational study that was initi-
ated to establish a set of recommendations for the collection of efficacy,
safety and quality-of-life data in a structured longitudinal manner, and
to coordinate the use of miglustat for the treatment of GD1 in real-life
settings. All consecutive patients with confirmed GD1 who fulfilled
criteria to receive miglustat therapy are included. The study was de-
signed in accordance with recommendations from the EuropeanWork-
ingGroup on GDAdvisory Council [20], andwas subsequently approved
by theEthics Committee for Clinical Investigation of Aragon (CEICA) and
was conducted in accordance with the Declaration of Helsinki of 1975,
as revised in 2008.ood Cells Mol. Diseases (20162.2. Study treatment
Miglustat therapywas administered according to guidelines devised
by the Spanish Foundation for the Study and Therapy of Gaucher Dis-
ease (FEETEG) in order to optimize and standardize miglustat use. All
treated patients received miglustat 100 mg three times daily orally,
with dietary recommendations to exclude carbohydrates during the
first weeks of starting therapy.
2.3. Efficacy and safety assessments
Specific assessment methods have been described in detail in previ-
ous publications [15,16]. Effects on core GD disease parameters were
considered in relation to established therapeutic goals for anaemia,
thrombocytopenia, hepatomegaly and splenomegaly according to re-
ports published by Pastores et al. [6,7]. Specific assessment methods
have been described in detail in previous publications [15,16].
Briefly, organ volumes were evaluated annually at local sites, and
were corroborated in a subset of patients usingmagnetic resonance im-
aging (MRI). Bone marrow infiltration was evaluated every 12 months
based on the published S-MRI scoring protocol for Gaucher cell infiltra-
tion patterns in the spine, pelvis and femur [21]. Bone mineral density
(BMD) was evaluated using ultrasound measurements in both heels
(calcaneus bone) using a Cuba Clinical Bone Densitometer (Norland
Medical Systems). Broadband ultrasound attenuation (BUA), speed of
sound (SOS), and estimated BMD were all determined at baseline and
after 2 and 4 years of therapy. Plasma chitotriosidase (CHT) activity
and CLL18/PARC concentration were analysed in the FEETEG laboratory
using a 4-methylumbelliferyl-b-D-N,N′,N″ triacetylchitotrioside sub-
strate and enzyme-linked immunosorbent assay, respectively. Safety
and tolerability assessmentswere based on patient- and treating-physi-
cian reports.
2.4. Data analysis
Descriptive statistics for continuous variables, sample size (n), mean
and its standard error (SE), standard deviation (SD), median, and range
were calculated for haemoglobin (Hb) concentration, platelet count,
spleen volume, liver volume, and changes in biomarker activity. Spleen
and liver volumes were calculated as multiples of normal (MN; where
normal spleen volume is 2 mL/kg of body weight and normal liver vol-
ume is 25 mL/kg of body weight). Patient numbers and percentages
were calculated for categorical variables based on patients with avail-
able data per time point.
Bone parameters were analysed by study cohort quartiles. Kaplan-
Meier analysis estimate of the probability of drug discontinuation or
death. Changes between pre- and post-therapy S-MRI scores were
assessed using the paired t-test. For all statistical tests, differences
were considered significant if p b 0.05.
3. Results
3.1. Patients and disposition
To date, a total of 351 GD1 patients have been diagnosed in Spain
[22]. Between 2004 and May 2016, 63 patients from 43 hospitals were
treated with miglustat, among whom 20 (32%) received miglustat as
first-line therapy and 43 (68%) switched from previous ERT (mean
[range] ERT duration 6.9 [1.2–13.5] years).), http://dx.doi.org/10.1016/j.bcmd.2016.10.017
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grouped according to treatment path (i.e., treatment naïve or switched),
are summarized in Table 1. Overall, the mean (range) age at the time of
GD1 diagnosis was 34.8 (2–79) years and themean (range) age at initi-
ation of miglustat therapy was 43.7 (18–79) years.
Of 63 patients exposed tomiglustat, a total of 24 discontinued treat-
ment during the study observation period: 11 due to uncontrolled gas-
trointestinal disturbances, six due to an increase in bone infiltration
(two of whom had a bone crisis), one patient due to weight loss N10%,
one due to persistent headache (during the early stages of treatment),
and two due to planned pregnancy.
Five patients died during the study observation period due to rea-
sons that were not considered related to treatment, including two
cases of cancer in treatment-naïve patients (melanoma after 2 years
and endometrial adenocarcinoma after 3 years of follow up), and one
case each of myocardial infarction, liver failure and progressive general
deterioration in switch patients.
Currently, 39 (62%) patients continue to receive miglustat therapy
(mean [range] age 44.2 [20–68] years; 41.0% female), among whom
14 (36%) were treatment-naïve at commencement of miglustat and
25 (64%) had previously received ERT for ≥5 years. Themedian previous
ERT dose among switch patients was 30 U/kg once every other week:
nine were receiving ERT at N30 U/kg every other week at switching.
Among all patients who currently remain on miglustat, the mean
(range) overall duration ofmiglustat treatment is 89.2 (6–120)months.
Thirty-one patients (79%) have received miglustat for ≥5 years, and 15
(38%) have been onmiglustat for 12 years. All currently treated patients
have undergone at least one post-baseline follow-up visit, providing a
median (range) efficacy follow-up period of 99 (9–120) months.
3.2. Core disease parameters
Absolute values of Hb concentration, platelet count, spleen and liver
volume, and plasma CHT and CCL18/PARC levels in the entire cohort
(N = 63) at baseline and annual follow-up are summarized in Fig. 1.
Haemoglobin concentration increased between baseline and Year 4,
and appeared stable thereafter (Fig. 1a). Overall, there were no statisti-
cally significant differences in mean Hb versus baseline at 2, 5 or
10 years of follow up. Among patients with available data and anaemia
at baseline (n = 6), the mean (SD) change in Hb concentration versus
baseline was +1.3 g/dL (0.74) at 6-month follow up, and Hb remained
stable thereafter. In switch patients with available data (n=3), Hb con-
centration was b12 g/dL at the time of switching and improved by
+1.8 g/dL (0.39) versus baseline at subsequent follow up.
Platelet counts appeared stable over the 12-year course of follow up,
and therewas no statistically significant overall change from baseline in
mean platelet counts at 2-, 5- or 10-year follow-up (Fig. 1b). Among 20
patients with available data at 10-year follow up, absolute values had
decreased slightly, with a mean (range) change from baseline of−35
(10–86) × 109/L. Four patients with available data had a platelet count
b100 × 109/L (70, 77, 90 and 95 × 109/L) at final follow up.Table 1
Patient and disease characteristics at baseline (all miglustat-treated patients; N= 63).
Characteristic Treatment-naïve
(N = 20)
Switch
(N = 43)
Age in years, median (range) 55.7 (18–79) 48.4 (21–70)
Male: female, n (%) 11 (55.0): 9 (45.0) 23 (53.5): 20 (46.5)
Genotype, n (%):
N370S/N370S 6 (30.0) 3 (6.9)
N370S/L444P 6 (30.2) 13 (30.2)
N370S/other 8 (40.0) 19 (44.1)
Other/other 0 8 (18.6)
SSI, median (range) 6.6 (3.0–7.5) 6.6 (2.8–7.6)
Time on ERT (years) 0 6.9 (1.2–13.5)
Splenectomy (%) 3 (15.0) 7 (16.3)
ERT, enzyme replacement therapy; SSI, severity score index.
Please cite this article as: P. Giraldo, et al., Blood Cells Mol. Diseases (2016Spleen and liver volumes did not show statistically significant varia-
tions over the 10-year course of follow-up (Figs. 1c and d).
3.3. Biomarkers
At 10-year follow up, we observed wide variability in CHT activity
with increased mean in 24/42 (57%) patients with available data
(+2448 nmol/mL·h; range 135–13,687), and CCL18/PARC was also in-
creased in 18/42 (43%) patients (mean 250 ng/mL; range 19–1016).
These increases were not statistically significant versus baseline values
(p=0.41 and p=0.08, respectively) andwere not associatedwith clin-
ical manifestations (Figs. 1e and f).
3.4. Therapeutic goals analysis
Over 80% of patients achieved or maintained accepted therapeutic
goals for GD1 in the switched on miglustat therapy during the study
observation period. Haemoglobin concentration was normalised
(to N11.0 g/dL for women; N12.0 g/dL for men) after 12–24 months
on miglustat, independent of transfusions. No symptoms of anaemic
syndrome were identified over the initial 2 years of follow up. Overall,
Hb values were stable at 2-year follow up, and remained so up to
the end of the 10-year observation period (Fig. 1) Platelet counts in-
creased in treatment-naïve patients with moderate thrombocytopenia
(40–99 × 109/L) during the first 12 months of miglustat therapy, and
continued improvement up to 60 months. Among switch patients,
platelet counts were maintained at N100 × 109/L throughout 10-year
follow-up. The accepted goal for reducing spleen volume is a 30–50%
decrease in the first year and 50–60% at 5 years, and the target
reduction in liver volume is 20–30% over 12–24 months and 30–40%
after 3–5 years. Both of these goals were achieved during miglustat
therapy in this cohort.
3.5. Bone parameters
Themajority of patients with available bone data (32/43 [74.4%]) re-
ported an overall reduction in chronic bone pain. Mean (range) overall
S-MRI scores at baseline and 2-year follow up were 9.6 points (0–25)
and 7.2 points (0−21), respectively (p = 0.042). The mean S-MRI
score in the treatment-naïve group was 8.8 points (0–14) and 10.0
(0–25) in the switch group at start therapy. Ultrasound examinations
of calcaneus bone among a total of 24 patients who received miglustat
for ≥2 years (seven treatment-naïve and 17 switch patients) indicated
bilateral statistically significant increases in BMD (Table 2).
3.6. Tolerability and safety
Themost commonly recorded adverse events in thewhole study co-
hort (N=63)weremild-to-moderate gastrointestinal disturbances, re-
corded in 25 (40%) patients. Gastrointestinal adverse events were
reversible and were improved by adherence to a controlled diet or
disaccharidase supplementation in most cases. An exploratory
comparative subgroup analysis to identify differences in general
characteristics between patients who showed good gastrointestinal tol-
erability (n= 38) and those in whommiglustat was not well tolerated
(n = 25) did not reveal any significant differences (data not shown).
Gastrointestinal disturbances were recorded as the reason for miglustat
discontinuation in a total of 11 patients.
Thirty-eight patients (60%) experienced a reversible fine-hand
tremorwithout functional consequences during the first month of ther-
apy, but only 20 patients reported persistence of this effect after 4 years
on therapy. The tremor was reversible upon discontinuation of therapy.
Electrophysiological signs of subclinical peripheral neuropathy were
observed in 8% of patients beforemiglustat initiation. Periodic neurolog-
ical tests and electromyography (EMG) in these patients during follow-), http://dx.doi.org/10.1016/j.bcmd.2016.10.017
Fig. 1. Hb concentration (g/dL), platelet count (×109/L), liver and spleen volume (MN), CHT activity (nM/mL·h) and CCL18/PARC concentration (ng/mL) during long-term miglustat
therapy in all miglustat-treated patients (N= 63) No significant difference in mean Hb concentration at baseline compared with values after 2 years (p = 0.570), 5 years (p = 0.500)
or 10 years (p = 0.778) of miglustat therapy; no significant difference in mean platelet counts at baseline compared with values after 2 years (p = 0.577), 5 years (p = 0.793) or
10 years (p = 0.657) of miglustat therapy. In spite of wide variability in CHT activity and CCL18/PARC concentration there are not significant differences at baseline compared with
values after 2, 5 and 10 years (CHT Baseline vs 10 years (p = 0.41)), (CCL18/PARC Baseline vs 10 years (p = 0.08)).
Table 2
Broadband ultrasound attenuation values, and derived Z-score and T-score in calcaneus bone assessments in 24 patientsb treated with miglustat for 2 years.
Limb BUAa, mean (range) Pc Score Z-T score, mean (SD) Change Pc
Baseline Month 24 Baseline Month 24 95% CI
Right 82.4 (47–101) 84.2 (66–100) 0.04 Z –1.3 (0.9) –1.1 (0.9) 0.09, 0.42 b0.01
T –1.3 (0.9) –1.3 (0.9) 0.09, 0.48 b0.01
Left 74.2 (32−100) 75.6 (48–101) 0.06 Z –1.1 (0.9) –0.9 (0.5) 0.09, 0.30 b0.01
T –1.5 (1.1) –1.1 (0.4) 0.08, 0.45 b0.01
a Broadband ultrasound attenuation.
b Data based on seven treatment-naïve patients and 17 previous ERT patients with available data.
c P-values related to a comparison of month 24 values with baseline values, as assessed based on the paired t-test.
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during follow-up two patients developed a peripheral neuropathy.
No patients in the study appeared to develop cognitive deterioration
during miglustat therapy for up to 12 years. Weight loss N10% was re-
ported for three patients (4.7%). Amongpatientswho reported gastroin-
testinal disturbances as the reason for miglustat discontinuation, six
also showed increased bone infiltration, two had a bone crisis, and
one had N10%weight loss. One patient also had Gaucher cell infiltration
in the myocardium (at biopsy), and one had persistent headache that
led to discontinuation in the early stages of treatment.
Kaplan-Meier estimate of the probability of drug discontinuation or
death in the entire cohort (n=63) indicated a tendency to lower over-
all rate of miglustat discontinuation among treatment-naïve patients
compared with the switch group, but the comparison by Log-Rank
test is not significant. (Fig. 2).
4. Discussion
We present long-term data on changes in haematological and
visceral indices and biomarkers in both treatment-naïve and ERT-
stabilized adult GD1 patients treated with miglustat for up to 12 years
in clinical practice settings. To our knowledge, this report represents
the longest real-world assessment of the effectiveness and safety of
miglustat in GD1 to date, and builds on previous findings from this co-
hort and on data reported in other open-label studies and case series
[15,17,18,19,23,24].
Throughout up to 12 years of therapy with miglustat in this Spanish
cohort, Hb concentration remained largely unchanged and platelet
count remained stable, with moderate fluctuations. Liver and spleen
volumeswere also stable during followup. Thesefindings are consistent
with accepted therapeutic goals for GD1 therapy in treatment-naïve pa-
tients reported by Pastores et al. in 2004 [6,7]. The data from this cohort
add further support for the use of miglustat in patients who refuse ERT
or who are otherwise unsuited to regular intravenous infusions. The ef-
ficacy of miglustat as a maintenance monotherapy for GD1 over
24months has previously been reported in 36 patients previously stabi-
lized with ERT [25]. In the observational, retrospective multicentre
study in 115 miglustat-treated patients reported by Kuter et al. [19],
Hb and platelet counts tended to increase in treatment-naïve patients
during miglustat therapy, and remained stable or decreased slightly in
ERT pre-treated patients.
The efficacy of miglustat may result from twomechanisms of action.
Besides inhibiting substrate formation, miglustat may also accelerateFig. 2. Estimated probability to discontinuation of miglustat therapy (all miglustat-treated
patients; N = 63) Data censored to account for discontinuation of miglustat therapy or
death from any cause (Log-Rank test 0.482).
Please cite this article as: P. Giraldo, et al., Blood Cells Mol. Diseases (2016destruction of the glycolipid complex by increasing glucocerebrosidase
(GC) activity through a chaperoning function. The chaperoning effect
of miglustat was shown to be specific for glucocerebrosidase with mu-
tations in the catalytic domain (domain III) [25,26]. In vitro studies dem-
onstrated that glucocerebrosidase activity was increased 2.5-fold in
cells transfected with the N370S mutation when cultured in a medium
containing miglustat [26]. It is therefore noteworthy that the majority
of the patients in our series had at least one glucocerebrosidase gene al-
lele with the N370S mutation.
Disease biomarkers during miglustat therapy showed a tendency to
increase during followup in this studywithout any appearance of clinical
manifestations. It is therefore possible that differences in patient compli-
ance or inter-individual variations affected the observed CHT values.
Overall our data suggest that plasma CHT and CCL18/PARC might not
fully reflect systemic disease burden in GD1, and cast doubt on the strict
validity of these biomarkers in clinical decision making [25].
Bone disease is the most frequent and debilitating manifestation of
GD1 [27]. A prospective pooled analysis of data from three open-label
studies with miglustat as monotherapy for GD1 demonstrated that
miglustat reduces the incidence of bone pain and improves BMD [28]
– an effect thought to stem from the fact that this agent has a wide dis-
tribution throughout body tissues, including bone [29]. Early and
sustained increases in lumbar spine and femoral neck BMDwere report-
ed, with significant increases from baseline evident at 6, 12 and
24 months [28]. For these reasons, miglustat might be a valuable treat-
ment option for the improvement of bone disease in GD1.
Based on the current cohort we assessed long-term changes in BMD
and bone elasticity using ultrasound methodology in the calcaneus
(heel) bone. Data from heel bone ultrasound analyses have been
shown to correlate well with DXA measurements, although ultrasound
data indicate greater degrees of change over time compared with DXA
findings [30]. Evaluations in our patients were performed by the same
radiologist using the samemachine, and according to the same protocol,
at baseline and follow up, and showed statistically significant increases
of both ultrasound-derived BUA and DXA-derived Z- and T-scores after
2 years on miglustat. The majority of patients in the whole cohort also
showed improvements in chronic bone pain and Gaucher cell infiltra-
tion of bone (as measured by S-MRI) during 2 years on therapy.
Avascular necrosis was observed in two patients (3.1%), both of
whom were non-splenectomized switch patients, and one of which
did not demonstrate good adherence to miglustat therapy. GD1 is a
chronic disorder and requires an effective and continuous treatment
regimen on a life-long basis. For patients on prolonged oral therapy
the correct adherence to every day therapy is a widespread problem
[31].
Gastrointestinal tolerability showed a high degree of individual var-
iability in this study, which was possibly related to differences in food
habits and levels of disaccharidase inhibition (Medrano B et al. in
press). Similar to therapies for other chronic diseases such as diabetes,
arterial hypertension and dyslipidaemia, gastrointestinal disturbances
such as diarrhoea, flatulence and vomiting are known, common effects
seen duringmiglustat treatment [12,13]: it has been estimated that ap-
proximately 56% of drug therapies have an influence on gastrointestinal
function. Although uncomfortable if they occur, gastrointestinal adverse
events related tomiglustat therapy are reversible and do not require in-
tensive therapy inmost cases [31].While generallymoderate in intensi-
ty and not related to severe complications, gastrointestinal effects were
the most frequent reason for miglustat discontinuation in this cohort,
which is in line with previous published data [31].
Tremor was the main neurological side effect observed during the
study, particularly at commencement of treatment. Two new cases of
peripheral neuropathy with clinical symptoms that were attributable
to miglustat were observed in this study. Previous published data dem-
onstrating that peripheral neuropathy should be considered part of the
natural history of GD1 [32,33,34], and data from up to 9 years of post-
marketing clinical safety surveillance for miglustat that showed no), http://dx.doi.org/10.1016/j.bcmd.2016.10.017
6 P. Giraldo et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxassociation betweenmiglustat and peripheral neuropathy [17,23], how-
ever treating physicians should be aware of this association to improve
early detection.
No other adverse long-term effects ofmiglustat treatment have been
documented [17,23].
5. Conclusions
The first trials of oral SRTwithmiglustat in GD1 began N16 years ago
[14,25,35,36]. As a result there is now considerable, widespread experi-
ence of its use in clinical practice. The general opinion regarding oral
miglustat therapy is that it is satisfactory both in terms of controlling
disease in treatment-naïve patients and in maintaining disease stability
in patients previously stabilized on ERT.Miglustat is not a curative ther-
apy, but it does prevent excess lipid storage in the spleen, liver and bone
marrow, and has been shown to maintain disease stability in line with
established therapeutic goals in the majority of patients. Overall, long-
term treatment with miglustat appeared associated with only mild-to-
moderate adverse events in this Spanish cohort. Importantly, miglustat
also provided additional benefits on bone parameters, with statistically
significant decreases in bone marrow infiltration (as measured by S-
MRI) and increases in BMD (as measured by BUA and DXA). Plasma
CHTactivity and CCL-18/PARC concentration showed a trend to increase
over time, but did not reach initial values. As an aside, biomarker alter-
ations did not correlate with clinical.
As we have commented in previous reports [15,16], and reinforce
now with the benefit of accumulated experience, miglustat appears to
be a valid alternative to ERT as a maintenance therapy in GD1. This
agent also has the added advantage of convenient oral administration,
which serves as a useful therapeutic option for maintaining efficacy in
patients who discontinue ERT due to preference, holidays, travel, work
or other commitments.
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